{"name":"Hengrui Therapeutics, Inc.","slug":"hengrui-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"HTI-2088","genericName":"HTI-2088","slug":"hti-2088","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"HTI-2088","genericName":"HTI-2088","slug":"hti-2088","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNMGhxWlVSM2wzdUNBZFM3bUl5b2VqNW01YlN5bmtkSUZ2ZFJPWTFvX3pnRGg0WGF5ekRiU1d2ZGQyTVljdjVtU1lPalJ1N0RfWmFOanUxa3J0WWR5c0ZOVWtOMmVCNlpMdzFHSlVuNFZ2WGdvaDBNbngwQkswajVOaGJwXy1Teml1anZoZGxfa1hWdw?oc=5","date":"2026-02-10","type":"trial","source":"Yahoo Finance","summary":"Kailera Therapeutics and Hengrui Pharma Report Positive Topline Data from Phase 2 Obesity Trial of Oral Ribupatide - Yahoo Finance","headline":"Kailera Therapeutics and Hengrui Pharma Report Positive Topline Data from Phase 2 Obesity Trial of Oral Ribupatide","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiuwJBVV95cUxQVGFUSEpxTE0wSjE1TWZlcVNaclVaWFB0bXpQYVZpeFZLdEpwYUpBVEk4NVRoRkpFYU50cm15enpLZU56NXR6QklNdE5mUkVtZ203UHQxRmtWOXlHRzNOdF9ZSGRiVENIQ0hoblE3RUhaNkVnT0pPd0tTV2U4enNtdUpYRXVYRWtOcjNQUUdHS3Q3M0NHS19Yem5ONkVGVndPMWI3am1vSlZHUmJzamJ0NWFpRDQ3UTFGRUJ5b0tSeDlKb0l3VXZBTUtyVXhnV0xaQVRQN0xMYkJqNEJiaTJpVWVwem9SakhLSnYwaXN5WlJUT0o4VEZTZjJSOHlfQzU3bmluMEVZZ1lfUWE0Z015OXJrZlV1Y3ZaQjlrWEw1VmVQVGZ2M2c2a01JMnQ4Mlpxcl91UEdWUl8xdUk?oc=5","date":"2025-11-04","type":"trial","source":"GlobeNewswire","summary":"Hengrui Pharma and Kailera Therapeutics Announce Additional Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531 - GlobeNewswire","headline":"Hengrui Pharma and Kailera Therapeutics Announce Additional Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP R","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNRm14a3pUQmM0bGJjSU5EQ3pPZU03cXNUcWhzcF9LbE1GTnI3Y0hhQmhTU3dXcEdCSERhS0cydEVkSG5PSm9sVXRaZ3BiN2pOdDlQNVRrMHFaTm1qSTFCUk9ZSGZPQnpUakZDVXFzM1I0T3VlYmlfREtiZ0Z4d3ItdGxqb2ZMMTlpM19rZHJnYWJNN2Zl?oc=5","date":"2025-10-21","type":"trial","source":"Yahoo Finance","summary":"Hengrui Pharma and Kailera Therapeutics Announce Phase 3 HRS9531 Obesity Data Presentation at ObesityWeek® 2025 - Yahoo Finance","headline":"Hengrui Pharma and Kailera Therapeutics Announce Phase 3 HRS9531 Obesity Data Presentation at ObesityWeek® 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQOXRpUnZNTXVtX3F3SHFsM1ZSY3pKd1lGajE1NjhXeGlwbnZLS0hEYVd4V2kxYTJxMGw4Q3FFaVNkM0R5a2E0U2hXUnFQUWNKUEdBUGFENVVRb1BBdDRPelpBM2pIMF91a2I0eEJaSXpKdzhFd2F5Y3ZPX3pvcy1HQU5oYXlzM2JGVFQxLUxOY19JMFdKZ0VYQTJHSWFkdw?oc=5","date":"2025-09-25","type":"deal","source":"BioWorld News","summary":"Hengrui and Glenmark sign $1B deal for HER2-targeting ADC - BioWorld News","headline":"Hengrui and Glenmark sign $1B deal for HER2-targeting ADC","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-07-28","type":"pipeline","source":"South China Morning Post","summary":"GSK to pay Hengrui US$12.5 billion for global rights to 12 drug projects - South China Morning Post","headline":"GSK to pay Hengrui US$12.5 billion for global rights to 12 drug projects","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxPandkMnQwNEl6TFNNWFJPMFF6Z3c4MlFzbEZKUnQwbnpUYm91eFQtSGVYMDN1MS1xMXJLdGpWckIweGM1bEl0S0ZQRXU4UkY2VTFrWERkNjBYN1VrcjkzVGMxbHBmWV9QZ2NOZW5pUE42LVlRX0Jpa0xrT2FCLWllU1BCVV8wSmd6ZzdnZmJuNlU?oc=5","date":"2025-07-28","type":"pipeline","source":"GSK","summary":"GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology - GSK","headline":"GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflam","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOY1cta19lTmdVSkppd3h2MjRpd3BNZW82M0VqMU5QUGtvckpzak5ydE9hVE5sZnBOOUJTejQ5QjZtUG45NFNvNU9Dd0ZkVnNXZmJFcDdNbW1nSXVNU1Y3S2xiSHpodHdlZDFNTHdoTXYtRXRLU2FDTWNwbVpTZG1oRl9pS2o3eHU5c2ZTd0l3cjdTSnhGRkFqZUVpLVNxQ3h1MnlVV1h5eGI?oc=5","date":"2025-07-28","type":"deal","source":"Bloomberg.com","summary":"Hengrui Shares Jump on GSK Deal Worth Up To $12 Billion - Bloomberg.com","headline":"Hengrui Shares Jump on GSK Deal Worth Up To $12 Billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wJBVV95cUxOMHAtNnZiWWdmODlWMVh5OUthTVd6YWlFMi1iMzVSN0Y2NWdZcUc5dzhLSC1mMFB3QXZPMS02SE9xSTg1ckpwSGdiZjExb2otQ1FSc1o2Qk51bkE3OGtLV3lfRXJfUTJ0UzlRcUplaGxkVThiZ2NXZ21UUk9sTlBxcks0dFpZU0poMWZOeHlldEJ3NFpLZHpnZWY0LUtqMmlzYnA0SHdrU0FkVEFyTW80ZVFGenFHN2hiaktsczVjNmNrSlB4YXVIa0FWUnQySXdMSTB0NEJQVmgyQUxRU1ZyMkNiRTI2TEx2eVhmd2w1MmExUWhiR3JGSkJmdzdOdFM1Rk14VWZ4ZkZhb01Ya1AtbnlXSVVvdnRWaTdRR0R1SHk0OF9JUXZ1NVBfU1JYUmZvQ1hURW1oRXg5QUhiZXV4V2JBTDF2NFJPVGF0cm1RTGNTRVZ1c1Bj?oc=5","date":"2025-07-22","type":"pipeline","source":"prnewswire.com","summary":"IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC - prnewswire.com","headline":"IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywJBVV95cUxQWkNtOGt5dlB2R3VpblEtTnQ2bWUwelpVZ2wtbF9MNEFKcnR3LTlHT2UxcDZWN25yQnFBQ05FSTJYbnIwNHNFQ2l3bThvZTNmTG9nOFFQTzZPNURDcUxwZVBHQXk0VjZCa3VrazR5T0ZVSVhLSGRheFB3eXktd0EtbWZjQVM0VkRyWWp3SURWTVFSZlZoYmFMa2ZlZzh2SnNES2stX1dDRjV6d1ZsNGlVcmFBSjVYQklidVdSWG9KdTF0R3lfbURBeU1jTTh1T3dZcDZCOEd1N1ZpMFB5NXhZOHdZb1ctTjdaeERwX3F4Tlp2VTNRSnR6SkR6ZEVXbzVhTDg2djROb3FiUEozTlVnN1VpZEJKNzZxT3lySzRJam5adjByb0dSTmZsOXphRXB6WjdSeV8xSDJRVk5JQ3haOGJQLVd0cjJNZXZr?oc=5","date":"2025-06-16","type":"pipeline","source":"GlobeNewswire","summary":"Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics - GlobeNewswire","headline":"Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTE9VRThrWERwUEJGTnMzSERyVUxMbzBSaHo5MGloVjUyTFpnM1pIX2NtenI4OXdrQWVKR1llcjkycTZZcGJMZ3ZFaFhDdGFOVk9aLTVsZ1NKTkI3UThFcllYcDktMUJPdE9qZHVfa0FBUWc?oc=5","date":"2025-05-23","type":"pipeline","source":"Law.asia","summary":"Hengrui raises HKD9.8bn in HK’s largest pharma IPO in 5 years - Law.asia","headline":"Hengrui raises HKD9.8bn in HK’s largest pharma IPO in 5 years","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwJBVV95cUxQRVl0LWhzemhlaWVTTnpEd0VsT2NnemdkcU1zM3NNSlRvQktPVTMxMzNJVFJ4NFE2SnRkWnJTNnhzUGs3N29WZFBNUVVGZ0Q3UzBhRFdHSExRTFBfOGo3cjFhSDNhc1JNZ1VnNFI5N29TX0N4WDBrOXJ0MUtabXpBMDhmY0JBRHd6WVM0eEswZ241TnQySUdUZHVYRkJRdEpjeXFaVUl1WUdOZUFXZ3N6bFBBLTdmZ0VWeS1Uak9YRUN3QTIzSjYtMUV1N0hTVl9LbE1MV3JqdWV0RXpLUVVkSmN1LVAycjBuX1hicWlpSUlXZ183M3VvVWlCamdNajlUbFVXM1N2SUFKdlBHRVVjS0dISUxMZEVJVjFLMC1ndm9MQVlGcDNRclIxc1FMdUFFNGJrd0hQRjR6aEhiOGp0bDF2V1dRUkxLN2tfQzFWQQ?oc=5","date":"2025-03-25","type":"deal","source":"businesswire.com","summary":"Merck Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascular Disease from Jiangsu Hengrui Pharmaceuticals Co., Ltd. - businesswire.com","headline":"Merck Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQVHJ6OENrOWhKanJya2tIelhhd0o0TlYxeGlTTld5c2k3Q3NFUGRWQ09iLTNnd01IQnV3dlpJVzllanhtbUZNZ3pkdG5HdVE5OTR0UkJJcDJDNDR0SW1wel9KemNLbkNqZ0sxeEEzUzRObWVVcTg4dFE2UjNqYXo1aUlJTEJXQlFGZ2Fjc1hwRzZqcS1WWGwySDZ5XzZWY1k?oc=5","date":"2025-03-21","type":"regulatory","source":"Fierce Pharma","summary":"FDA rejects Hengrui, Elevar's PD-1 cancer drug combination—again - Fierce Pharma","headline":"FDA rejects Hengrui, Elevar's PD-1 cancer drug combination—again","sentiment":"negative"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}